Sign up to save your podcasts
Or
Share Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
87 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners